Pear Therapeutics, Inc.

Thimble Point Acquisition Corp. (Nasdaq: THMA), sponsored by Thimble Point LLC, completed its initial public offering in 2021 with a focus on the healthcare and life sciences sector. The company filed an 8-K with the SEC on December 8, 2021 in connection with its planned business combination with Pear Therapeutics, Inc., a digital therapeutics firm developing prescription software-based treatments for behavioral health and substance use disorders. The merger subsequently closed and the combined entity traded publicly under the ticker PEAR; Pear Therapeutics later filed for bankruptcy protection in early 2023, making THMA a completed de-SPAC transaction. Sign up at SpacDesk for full filings, deal timelines, and analytics on THMA and the broader SPAC market.